NCT00272740View on ClinicalTrials.gov

SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

93

Participants

Timeline

Start Date

March 31, 2000

Conditions

Breast Neoplasms

Interventions

DRUG

Fulvestrant

Trial Locations (8)

Unknown

Research Site, Leuven

Research Site, Aarau

Research Site, Bern

Research Site, Geneva

Research Site, Lausanne

Research Site, Mendrisio

Research Site, Milano

Research Site, Sankt Gallen

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY

NCT00272740 - SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer | Biotech Hunter | Biotech Hunter